



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Dave Yeung  
✉ dave.yeung@takeda.com

<sup>†</sup>Affiliation at the time of the study

RECEIVED 08 January 2025  
ACCEPTED 23 January 2025  
PUBLISHED 14 February 2025

## CITATION

Sexton D, Faucette R, Rivera-Hernandez M, Kenniston JA, Papaioannou N, Cosic J, Kopacz K, Salmon G, Beauchemin C, Juethner S and Yeung D (2025) Corrigendum: A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema. *Front. Allergy* 6:1557356. doi: 10.3389/falgy.2025.1557356

## COPYRIGHT

This work is authored by Sexton, Faucette, Rivera-Hernandez, Kenniston, Papaioannou, Cosic, Kopacz, Salmon, Beauchemin, Juethner, and Yeung. © 2025 Takeda Pharmaceuticals USA Inc. for Sexton, Faucette, Rivera-Hernandez, Kenniston, Papaioannou, Cosic, Kopacz, Salmon, Beauchemin, Juethner, and Yeung. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema

Dan Sexton<sup>1†</sup>, Ryan Faucette<sup>1†</sup>, Melody Rivera-Hernandez<sup>1†</sup>, Jon A. Kenniston<sup>1†</sup>, Nikolaos Papaioannou<sup>1†</sup>, Janja Cosic<sup>1</sup>, Kris Kopacz<sup>1</sup>, Gary Salmon<sup>2</sup>, Chantal Beauchemin<sup>1</sup>, Salomé Juethner<sup>3</sup> and Dave Yeung<sup>1\*</sup>

<sup>1</sup>Takeda Development Center Americas Inc., Cambridge, MA, United States, <sup>2</sup>Charles River Laboratories, Harlow, United Kingdom, <sup>3</sup>Takeda Pharmaceuticals USA, Inc., Lexington, MA, United States

## KEYWORDS

biomarkers, phage display, bradykinin, plasma kallikrein, hereditary angioedema

## A corrigendum on

A novel assay of excess plasma kallikrein-kinin system activation in hereditary angioedema

By Sexton D, Faucette R, Rivera-Hernandez M, Kenniston JA, Papaioannou N, Cosic J, Kopacz K, Salmon G, Beauchemin C, Juethner S and Yeung D (2024). *Front. Allergy* 5:1436855. doi: 10.3389/falgy.2024.1436855

## Incorrect Copyright Statement

In the published article, there was an error in the Copyright statement. The statement was incorrectly written as “Copyright © 2024 Sexton, Faucette, Rivera-Hernandez, Kenniston, Papaioannou, Cosic, Kopacz, Salmon, Beauchemin, Juethner and Yeung”. The corrected statement is “This work is authored by Sexton, Faucette, Rivera-Hernandez, Kenniston, Papaioannou, Cosic, Kopacz, Salmon, Beauchemin, Juethner, and Yeung. © 2024 Takeda Pharmaceuticals USA Inc. for Sexton, Faucette, Rivera-Hernandez, Kenniston, Papaioannou, Cosic, Kopacz, Salmon, Beauchemin, Juethner, and Yeung”. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original authors and the copyright owner are credited and the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.